# Iron, copper and disulfide dysregulation: molecular crossroads of metabolic cell death in melanoma progression

**Authors:** Xinge Li, Yan Gao, Zhiyao Xing, Zichuan Liu, Xiangyang Zhang

PMC · DOI: 10.3389/fphar.2025.1685331 · Frontiers in Pharmacology · 2025-10-15

## TL;DR

This review explores how iron, copper, and disulfide imbalances drive metabolic cell death in melanoma and highlights new treatment strategies to overcome resistance.

## Contribution

The paper integrates mechanisms of ferroptosis, cuproptosis, and disulfidptosis and proposes novel therapeutic strategies for melanoma.

## Key findings

- Ferroptosis, cuproptosis, and disulfidptosis each have unique roles in melanoma progression and drug resistance.
- Combining metabolic cell death with immune regulation and nanoparticle delivery improves therapeutic outcomes.
- Key genes like SLC7A11, GPX4, and FDX1 are central to metabolic cell death mechanisms in melanoma.

## Abstract

Melanoma is a highly aggressive malignant tumor arising from melanocytes, with its incidence and mortality rates continuously rising in recent years, posing a major global public health challenge. Although traditional targeted therapies and immune checkpoint inhibitors have significantly improved survival in some patients, primary and acquired resistance remain common, creating an urgent need for new treatment strategies. In recent years, metabolic cell death, ferroptosis, cuproptosis, and disulfidptosis, has shown unique advantages in melanoma research. Ferroptosis directly kills tumor cells through iron-mediated lipid peroxidation; cuproptosis relies on copper-induced mitochondrial protein aggregation to inhibit tumor proliferation; disulfidptosis arises from disulfide stress caused by glucose deprivation. This review provides a detailed analysis on the mechanisms and metabolic competition paradoxes of these three types of metabolic cell death and integrates key metabolic nodes, such as related genes SLC7A11, GPX4, FDX1, LIPT1, and PPIC. Furthermore, we discuss innovative treatment strategies that significantly enhance therapeutic efficacy and overcome resistance, including the combination of metabolic cell death with immune cell regulation, nanoparticle delivery, and sonodynamic/photodynamic therapies. Ferroptosis, cuproptosis, and disulfidptosis each possess distinct advantages and characteristics in the context of melanoma development, metastasis, and drug resistance. Leveraging both their common and unique mechanisms offers new perspectives for improving treatment outcomes.

## Linked entities

- **Genes:** SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], FDX1 (ferredoxin 1) [NCBI Gene 2230], LIPT1 (lipoyltransferase 1) [NCBI Gene 51601], PPIC (peptidylprolyl isomerase C) [NCBI Gene 5480]
- **Diseases:** melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** PPIC (peptidylprolyl isomerase C) [NCBI Gene 5480] {aka CYPC}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, LIPT1 (lipoyltransferase 1) [NCBI Gene 51601] {aka LIPT1D}, FDX1 (ferredoxin 1) [NCBI Gene 2230] {aka ADX, FDX, LOH11CR1D}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}
- **Diseases:** Melanoma (MESH:D008545), malignant tumor (MESH:D009369), metastasis (MESH:D009362)
- **Chemicals:** lipid (MESH:D008055), disulfide (MESH:D004220), copper (MESH:D003300), Iron (MESH:D007501), disulfidptosis (-), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12568384/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12568384/full.md

## References

188 references — full list in the complete paper: https://tomesphere.com/paper/PMC12568384/full.md

---
Source: https://tomesphere.com/paper/PMC12568384